In the BioHarmony Drug Report Database

"Preview" Icon

Palivizumab

Synagis (palivizumab) is an antibody pharmaceutical. Palivizumab was first approved as Synagis on 1998-06-19. It is used to treat respiratory syncytial virus infections in the USA. It has been approved in Europe to treat respiratory syncytial virus infections.

 

Trade Name

 

Synagis
 

Common Name

 

palivizumab
 

ChEMBL ID

 

CHEMBL1201586
 

Indication

 

respiratory syncytial virus infections
 

Drug Class

 

Monoclonal antibodies: humanized, antiviral indications

Image (chem structure or protein)

Palivizumab structure rendering